Navigation Links
Patient Safety in Challenging Economic Times is Focus of NPSF Annual Congress on May 20-22
Date:1/13/2009

BOSTON, Jan. 13 /PRNewswire/ -- Responding to the increased risk to patient safety in an economic downturn, the National Patient Safety Foundation has announced that the 2009 NPSF Patient Safety Congress will directly address this issue through an extensive program of educational sessions designed to provide attendees with the new thinking and tools critical to keeping patients safe.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080307/AQF053LOGO)

This highly acclaimed annual event, to be held May 20-22 at the Gaylord National outside Washington, DC, boasts over 35 individual sessions targeting seven core areas essential to patient safety. In addition, insightful and inspiring plenaries are planned, including a town hall meeting with authors of the pivotal Institute of Medicine report "To Err Is Human" and distinguished members of the Lucian Leape Institute. Intensive full-day pre-Congress programs will also be offered, highlighted by a unique executive-level event providing case studies and discussion focused on successfully building a safety framework, setting safety and quality priorities, and ensuring critical physician engagement. Plus, the NPSF Congress provides direct access to a wide array of innovative solutions providers.

"These times demand increased vigilance from us all," explained Diane Pinakiewicz, President of the National Patient Safety Foundation, "and, as adversity threatens, it also sparks creativity and unique problem-solving, a mindset that is at the very heart of this year's Congress."

Widely recognized as the definitive patient safety event each year, the 2009 NPSF Congress will provide the new learnings, practical tools, and innovative solutions essential to keeping patients safe during these challenging times, and will offer unparalleled opportunities for attendees to collaborate with safety experts and influential healthcare leaders.

"Now more than ever, an unwavering focus on patient safety is critical," noted Ms. Pinakiewicz. "The risks are too great to respond otherwise."

Visit http://www.npsf.org for complete program details and registration information. Attendees may also register by calling 401.766.4904.

About the National Patient Safety Foundation

The National Patient Safety Foundation is an independent not-for-profit 501(c)(3) organization that has been diligently pursuing one mission since its founding in 1997 -- to improve the safety of patients. NPSF also occupies a unique position by virtue of its inclusive, multi-stakeholder approach, which fosters collaboration on the issue of patient safety.


'/>"/>
SOURCE National Patient Safety Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
7. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
8. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
9. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
10. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
11. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... , ... Charm Sciences, Inc. is pleased to announce the Charm® ROSA® Tetracycline-SL ... Shipments (NCIMS) Laboratory Committee and Appendix N Committee as a drug residue test kit ... NCIMS voted at its annual meeting in April, 2015 to establish a pilot program ...
(Date:7/24/2017)... , July 24, 2017 Intralytix, Inc. announced ... from Lesaffre, a French family group. This investment marks ... to develop and commercialize bacteriophage-based products, for various benefits ... interest. As ... designs manufactures and markets innovative solutions for baking, food ...
(Date:7/24/2017)... ... July 24, 2017 , ... Each year, Inavero’s Best ... proven their superior service quality as rated by hiring professionals and job candidates. ... based on service quality ratings from their placed talent. , Fewer than 2% ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... market news outlet had initiated coverage on Interpace Diagnostics. Interpace Diagnostics is ... exposure, progression and risk analysis from specific cancers in humans. , According ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):